Emergent plans to fix issues that halted vaccine production early as July -U.S. House memo

Emergent BioSolutions Inc told U.S. regulators it aims as soon as July to correct the problems at its manufacturing facility that ruined millions of COVID-19 vaccine doses, according to a private correspondence published by the U.S. House Oversight Committee.

Emergent Executive Chairman Fuad El-Hibri was repeatedly questioned at a Wednesday Congressional hearing about his ties to the Trump administration. An official under former President Donald Trump who oversaw the U.S. government's vaccine deal with Emergent had previously received consulting fees from the company, the U.S. House memo said. El-Hibri said it was "simply not true" that his relationship with Trump official Robert Kadlec influenced the U.S. government's contract award.